BioPharma Dive5d
GSK partners with Flagship startup to hunt for Parkinson’s drugs
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
FierceBiotech5d
GSK inks Parkinson's pact with Flagship's Vesalius for $570M-plus biobucks
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
Daily1d
GSK, Vesalius Therapeutics collaborate for novel treatments for Parkinson's disease
Cambridge: Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common ...
BioWorld4d
Vesalius-GSK $650M pact: Targeting Parkinson’s root causes
More than two years since emerging from stealth, Vesalius Therapeutics Inc. signed its first major pharma deal with GSK plc. Worth up to $650 million and possibly more if an option is exercised, the ...
Bloomberg L.P.5d
GSK Steps Up Parkinson’s Focus With US Biotech Deal
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
The Pharma Letter4d
GSK inks multi-target alliance with Versalius
Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...
The Victoria Advocate5d
Vesalius Announces Multi-Target Strategic Alliance with GSK to Develop Breakthrough Treatments for People Afflicted with Parkinson's Disease
Nov. 12, 2024 /PRNewswire/ -- Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, today announced a multi-target strategic ...
Morningstar5d
Vesalius Announces Multi-Target Strategic Alliance with GSK to Develop Breakthrough Treatments for People Afflicted with Parkinson's Disease
Morningstar brands and products Company Portfolio ...